McKesson's recent earnings report highlights a strategic shift in its business model, with oncology and technology units now contributing higher margins and faster growth compared to its traditional wholesale operations.
The company has completed the acquisition of Precision Medicine Group and is investing $1.4 billion for a 49% stake in Option Care Health, indicating a strong focus on expanding its specialty care services. Management has raised fiscal 2027 adjusted earnings guidance to a range of $45.60 to $46.40 per share, reflecting a growth rate of 17% to 19%.
Notably, while the legacy wholesale business generated 82.3% of revenue, it accounted for only 52% of adjusted segment operating profit, underscoring the profitability of the newer segments.
McKesson's planned separation of its Medical-Surgical Solutions unit, set to be renamed Wellverse, and the extension of its distribution agreement with CVS Health through June 2032, further enhance its long-term growth prospects.
The company is also generating strong free cash flow, with expectations of $4.5 billion to $4.9 billion for fiscal 2027, and has been actively repurchasing shares, which supports per-share growth.
Despite a significant stock rally, McKesson's valuation remains attractive compared to its historical median, suggesting potential for further upside as it continues to evolve into a more dynamic healthcare services provider